Tags

Type your tag names separated by a space and hit enter

A randomized multicenter trial of Crotalidae polyvalent immune F(ab) antivenom for the treatment of rattlesnake envenomation in dogs.
J Vet Emerg Crit Care (San Antonio). 2011 Aug; 21(4):335-45.JV

Abstract

OBJECTIVE

To determine clinical efficacy of the Crotalidae polyvalent immune F(ab) (ovine) antivenom (OPCA) against progressive crotalid envenomation in the dog as reflected in stabilization or improvement of snakebite severity scores (SSS). Additionally, due to the potential decreased half-life of the F(ab) antibodies in dogs we compared SSS between dogs receiving 2 different dosing regimes.

DESIGN

Prospective, clinical trial.

SETTING

Five veterinary emergency and critical care facilities.

ANIMALS

One hundred and fifteen client-owned Crotalid (rattlesnake) snake bitten dogs in whom worsening of the envenomation syndrome was observed before OPCA treatment.

INTERVENTIONS

In a multicenter randomized clinical trial a single dose (1 vial) of OPCA alone was compared with 2 doses (1/2 vial each) administered 6 hours apart. Standard supportive care was provided in all cases.

MEASUREMENTS AND MAIN RESULTS

Data were available for 115 patients, 9 of which were fatalities. All patients' clinical condition was documented with a standardized SSS system accounting for each major body system. Each fatality received maximum severity scores of 20. The mean severity score of the 115 patients decreased from 4.19 to 3.29 points and there was no difference between the 2 treatment groups. The mean severity score of the 107 patients without fatalities decreased from 4.16 to 2.15. Antivenin-related acute reactions occurred in 6 dogs (6%), and no serum sickness occurred within the 95 cases contacted at the 2-week posttreatment follow-up.

CONCLUSIONS

In the first randomized trial in dogs of antivenin in the United States, OPCA effectively stabilized or terminated venom effects. There were no statistical differences detected between treatment groups within the study time frame.

Authors+Show Affiliations

Reid Veterinary Hospital, Albany, OR 97321, USA. petersonkate@netscape.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

21827591

Citation

Peterson, Michael E., et al. "A Randomized Multicenter Trial of Crotalidae Polyvalent Immune F(ab) Antivenom for the Treatment of Rattlesnake Envenomation in Dogs." Journal of Veterinary Emergency and Critical Care (San Antonio, Tex. : 2001), vol. 21, no. 4, 2011, pp. 335-45.
Peterson ME, Matz M, Seibold K, et al. A randomized multicenter trial of Crotalidae polyvalent immune F(ab) antivenom for the treatment of rattlesnake envenomation in dogs. J Vet Emerg Crit Care (San Antonio). 2011;21(4):335-45.
Peterson, M. E., Matz, M., Seibold, K., Plunkett, S., Johnson, S., & Fitzgerald, K. (2011). A randomized multicenter trial of Crotalidae polyvalent immune F(ab) antivenom for the treatment of rattlesnake envenomation in dogs. Journal of Veterinary Emergency and Critical Care (San Antonio, Tex. : 2001), 21(4), 335-45. https://doi.org/10.1111/j.1476-4431.2011.00643.x
Peterson ME, et al. A Randomized Multicenter Trial of Crotalidae Polyvalent Immune F(ab) Antivenom for the Treatment of Rattlesnake Envenomation in Dogs. J Vet Emerg Crit Care (San Antonio). 2011;21(4):335-45. PubMed PMID: 21827591.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized multicenter trial of Crotalidae polyvalent immune F(ab) antivenom for the treatment of rattlesnake envenomation in dogs. AU - Peterson,Michael E, AU - Matz,Michael, AU - Seibold,Karen, AU - Plunkett,Signe, AU - Johnson,Scott, AU - Fitzgerald,Kevin, Y1 - 2011/05/16/ PY - 2011/8/11/entrez PY - 2011/8/11/pubmed PY - 2012/3/21/medline SP - 335 EP - 45 JF - Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) JO - J Vet Emerg Crit Care (San Antonio) VL - 21 IS - 4 N2 - OBJECTIVE: To determine clinical efficacy of the Crotalidae polyvalent immune F(ab) (ovine) antivenom (OPCA) against progressive crotalid envenomation in the dog as reflected in stabilization or improvement of snakebite severity scores (SSS). Additionally, due to the potential decreased half-life of the F(ab) antibodies in dogs we compared SSS between dogs receiving 2 different dosing regimes. DESIGN: Prospective, clinical trial. SETTING: Five veterinary emergency and critical care facilities. ANIMALS: One hundred and fifteen client-owned Crotalid (rattlesnake) snake bitten dogs in whom worsening of the envenomation syndrome was observed before OPCA treatment. INTERVENTIONS: In a multicenter randomized clinical trial a single dose (1 vial) of OPCA alone was compared with 2 doses (1/2 vial each) administered 6 hours apart. Standard supportive care was provided in all cases. MEASUREMENTS AND MAIN RESULTS: Data were available for 115 patients, 9 of which were fatalities. All patients' clinical condition was documented with a standardized SSS system accounting for each major body system. Each fatality received maximum severity scores of 20. The mean severity score of the 115 patients decreased from 4.19 to 3.29 points and there was no difference between the 2 treatment groups. The mean severity score of the 107 patients without fatalities decreased from 4.16 to 2.15. Antivenin-related acute reactions occurred in 6 dogs (6%), and no serum sickness occurred within the 95 cases contacted at the 2-week posttreatment follow-up. CONCLUSIONS: In the first randomized trial in dogs of antivenin in the United States, OPCA effectively stabilized or terminated venom effects. There were no statistical differences detected between treatment groups within the study time frame. SN - 1476-4431 UR - https://www.unboundmedicine.com/medline/citation/21827591/A_randomized_multicenter_trial_of_Crotalidae_polyvalent_immune_F_ab__antivenom_for_the_treatment_of_rattlesnake_envenomation_in_dogs_ L2 - https://doi.org/10.1111/j.1476-4431.2011.00643.x DB - PRIME DP - Unbound Medicine ER -